Universal influenza vaccine - Icahn School of Medicine at Mount Sinai
Alternative Names: cHA based vaccine - Icahn School of Medicine at Mount Sinai; Universal flu vaccine - Icahn School of Medicine at Mount SinaiLatest Information Update: 15 Apr 2026
At a glance
- Originator Icahn School of Medicine at Mount Sinai
- Class Adjuvants; Influenza virus vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 15 Apr 2026 Phase-II clinical trials in Influenza virus infections (Prevention) (unspecified route), prior to April 2026 (Dynavax Technologies pipeline, April 2026)
- 10 Feb 2026 Dynavax Technologies has been acquired by Sanofi
- 28 Nov 2023 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA